A direct and independent role of inflammation in atherothrombosis was recently highlighted by the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial， showing the benefit of inhibiting signaling molecules， eg， interleukins. Accordingly， we sought to devise a flexible platform for preventing the inflammatory drivers at their source to preserve plaque endothelium and mitigate procoagulant risk.

ApoE?/? mice，JNK2，atherosclerosis，endothelium，erosions，macrophages，peptide nanoparticles，perfluorocarbon nanoparticles，plaque，scavenger receptors，siRNA，thromb